MK-4815

MK-4815 (1.56-25 mg/kg; p.o.; first administered at 2 h post-infection, followed by twice daily dosing for 4 consecutive days; 9 doses in total) achieves 100% survival and no detectable parasites over a 74-day observation period in P. berghei KBG173-infected BALB/c mice at doses of 25, 12.5, and 6.25 mg/kg; 3.13 mg/kg prolongs survival by approximately 10 days but no mice survive to the end of the study, and 1.56 mg/kg shows no clear in vivo efficacy^[1].
MK-4815 (12.5 mg/kg; p.o.; administered once on the day of infection, followed by twice daily dosing continued for 1, 2, 3, or 4 days; 3-9 doses in total) achieves 100% survival with no detectable parasitemia for up to 95 days post-infection in P. berghei-infected BALB/c mice using the 2.5-day regimen; in the 1.5-day regimen, 40% of mice remain parasite-free throughout the entire study period, while the remaining mice show prolonged survival to days 13, 15, and 21 post-infection, respectively^[1].
MK-4815 (50 or 100 mg/kg; p.o.; single administration) shows complete in vivo efficacy in P. berghei-infected mice when administered on the day of infection^[1].
MK-4815 (50 mg/kg; p.o.; single dose; administered 2-96 h post-infection) achieves 100% parasite-free survival in P. berghei-infected mice when administered no later than 48 h post-infection; when administration is delayed to 72 or 96 h, 40% of mice remain parasite-free at 107 days post-infection, and the remaining mice exhibit a survival extension of more than 10 days compared with the sham-treated group^[1].